Virologic news - Trend weiter OK - 500 Beiträge pro Seite

[hubi3]

ViroLogic Appoints Edmon R. Jennings to Board of Directors
MONDAY, MAY 14, 2001 5:09 PM
- PRNewswire

SOUTH SAN FRANCISCO, Calif., May 8, 2001 /PRNewswire via COMTEX/ -- ViroLogic, Inc. (Nasdaq:VLGC) today announced the appointment of Edmon R. Jennings to the company`s board of directors.

Mr. Jennings is Chief Commercialization Officer of Pain Therapeutics, Inc., a specialty pharmaceutical company developing drugs for pain management. Prior to joining Pain Therapeutics in 2000, Mr. Jennings held senior management positions at Genentech, Inc. for 14 years, including Vice President of Corporate Development, Vice President of Sales and Marketing, and Vice President of Sales.

"We are excited to have Ed on our board because he is a proven leader who has built and motivated well organized, successful teams," said Bill Young, ViroLogic`s Chairman and CEO. "Ed`s 28 years of sales, marketing and business development experience, as well as his strategic vision and management expertise, will greatly benefit ViroLogic in our efforts to grow and diversify our business."

Prior to Genentech, Mr. Jennings held management and sales positions for over 10 years with Bristol-Myers Oncology and Bristol Laboratories, divisions of Bristol-Myers (now Bristol-Myers Squibb). He received his BA degree from the University of Michigan.

About ViroLogic

ViroLogic is a biotechnology company advancing the fields of individualized medicine and pharmacogenomics, helping to make them realities in healthcare around the world today. The Company discovers, develops and markets innovative products to guide and improve treatment of serious viral diseases such as AIDS and hepatitis. Its industry-leading expertise in virology, molecular biology, clinical research, engineering, information systems, and quality assurance has resulted in technology to assess drug resistance and susceptibility in viruses that cause these diseases, which affect millions of people worldwide.

The Company`s current products are designed to optimize HIV/AIDS treatment regimens, providing physicians with important information to help select appropriate drugs for their patients and leading to better outcomes and reduced costs. These products are also being used by nearly every major pharmaceutical company working to develop new and improved antiviral therapeutics that can be more effective in an increasingly drug-resistant environment.

MAKE YOUR OPINION COUNT - Click Here
http://tbutton.prnewswire.com/prn/11690X35594343

SOURCE ViroLogic, Inc.

CONTACT: Sidney Ho, Director of Public Affairs of ViroLogic, Inc.,
650-635-1100, ext. 7406, or [e-mail]

URL: http://www.virologic.com
http://www.prnewswire.com

(C) 2001 PR Newswire. All rights reserved.

KEYWORD: California
INDUSTRY KEYWORD: MTC
BIO
SUBJECT CODE: PER

[Siemm]

Hey Hubi mach doch noch eine 20 Tread auf

[t.1]

bei sehr geringen umsatz bis 1930uhr schwer zu beurteilen meiner ansicht nach...oder warted alles auf die FED....

[t.1]

@hubi
das ist der trend...gen süden hat mich schon stutzig gemacht jetzt stimmen die order größen wieder und es zeigt sich der trend.macht nichts da zukauf auf niedriegen kurs wieder möglich.wenn 3$ nicht halten wird es eng morgen.

[trendwatcher]

@hubi
@t. 1

Es war richtig (zunächst) zu verkaufen.
Der Biotech-Index ist kräftig im Plus:
Und Virologic verliert erneut deutlich (fast zehn Prozent).

Habe mir heute (2000) Antisoma gekauft (2,22 E).
Bei 4,44 werde ich auch davon die Hälfte abgeben.
So entsteht ein tradingfinanziertes "1000er-Depot" für meine Kids.

[hubi3]

Habe VIROLOGIC 3,92 Euro vorläufig glattgestellt.

Es dürften die Verkäufer überhandnehmen.

Der Chart deutet auf ein Doppelhoch hin.

[Bester]

hubi3

geb dir recht. Virologic hält sich meiner Meinung nach auffallend lange zwischen 3,8 und 4,3. Glaube, daß wir günstigere Einstiegskurse (evtl. 2,7 bis 3,1) sehen werden. Würde ein gutes Einstiegsniveau darstellen.

Übrigens: Ich bin erstaunt wie aktiv du bist.